title: The effects of ranibizumab injections on fluorescein angiographic findings and visual acuity recovery in age-related macular degeneration.
abstract: OBJECTIVE
  The objective of the study reported here was to evaluate the effect of ranibizumab on retinal circulation times and vessel caliber and to analyze the correlation of these factors with visual acuity (VA) prognosis in patients with age-related macular degeneration (AMD).
  
  
  METHODS
  This prospective cohort study included 52 eyes of 46 patients (mean age 73.5 years [standard deviation 7.7]; 28 males, 18 females). The study parameters were best-corrected visual acuity (BCVA), central macular thickness (CMT) (pre- and posttreatment: for 3 months after the last injection), retinal circulation times, diameter of retinal arteriole (DRA), and diameter of retinal vein (DRV) (pre- and posttreatment: after a loading dose of three consecutive injections of ranibizumab with a 4-week interval in the initial phase). The pretreatment, posttreatment measurements, and their differences were recorded for analyses. The injections were repeated when needed. Eyes were grouped into one of two groups according to VA recovery: Group 1, cases showing significant recovery of VA (n=21, 37%), and Group 2, cases showing preservation of VA (n=22, 42%) and deterioration of VA (n=11, 21%). Differences were compared statistically in and between groups. Logistic regression analysis was undertaken to determine the correlation of these parameters with VA recovery.
  
  
  RESULTS
  There was a significant reduction in DRA (P=0.007) and CMT levels (P<0.001) in both study groups after treatment. When the two groups were compared, the differences in pretreatment values of DRA (P=0.001), DRV (P=0.017), CMT (P=0.039), and mean BCVA (P=0.00) were found to be statistically significant. Posttreatment changes in DRA (P=0.013) and mean CMT (P=0.010) were found to be factors related to VA recovery by logistic regression analysis.
  
  
  CONCLUSIONS
  Our findings reveal that ranibizumab treatment is associated with decrease in DRA, CMT, and significant improvement in VA recovery. Further, taking into account the cases in which VA was preserved, when needed, ranibizumab should be re-injected after the loading dose.
authors.affiliation: Istanbul Education and Research Hospital, Eye Clinic, Istanbul, Turkey.
authors.forename: Hulya
authors.initials: H
authors.lastname: Gungel
authors.affiliation: Istanbul Education and Research Hospital, Eye Clinic, Istanbul, Turkey.
authors.forename: Ozen Ayranci
authors.initials: OA
authors.lastname: Osmanbasoglu
authors.affiliation: Beyoglu Eye Education and Research Hospital, Istanbul, Turkey.
authors.forename: Cigdem
authors.initials: C
authors.lastname: Altan
authors.affiliation: Kudret Eye Hospital, Istanbul, Turkey.
authors.forename: Deniz Oygar
authors.initials: DO
authors.lastname: Baylancicek
authors.affiliation: Beyoglu Eye Education and Research Hospital, Istanbul, Turkey.
authors.forename: Isil Basgil
authors.initials: IB
authors.lastname: Pasaoglu
keywords: central macular thickness; prognosis; retinal arteriole diameter; retinal vein diameter; vessel caliber